
-
Cyclacel Pharmaceuticals NasdaqCM:CYCC Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer medicines based on cell cycle, transcriptional regulation, epigenetics, and mitosis control biology in the United States. Its lead product Plogosertib or plogo, a solid tumors and hematological malignancies, which is in Phase 1/2 clinical trial. The company was founded in 1996 and is headquartered in Kuala Lumpur, Malaysia.
Location: Level 10, Kuala Lumpur, 592000, Malaysia | Website: https://www.cyclacel.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
566.7M
Cash
3.45M
Avg Qtr Burn
-2.689M
Short % of Float
0.30%
Insider Ownership
61.49%
Institutional Own.
6.64%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Oral Fadraciclib (CDK2 & CDK9) Details Solid tumor/s, Lymphoma, Cancer | Phase 2 Data readout | |
Oral Plogosertib Details Lymphoma, Solid tumor/s | Phase 1 Data readout |